BMS Receive the CHMP’s Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC After Prior Chemotherapy

 BMS Receive the CHMP’s Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC After Prior Chemotherapy

BMS’ Zeposia (ozanimod) Receives the US FDA’s Approval for Ulcerative Colitis

Shots:

  • The opinion is based on P-II CheckMate -142 study assessing Opdivo + Yervoy in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer whose disease had progressed during or after prior treatment with CT
  • If approved, Opdivo in combination with Yervoy will be the first dual immunotherapy approved in the EU in gastrointestinal cancer
  • The combination regimen receives the US FDA’s approval in Jul’2018 for adults and pediatric patients aged ≥12yrs. with MSI-H or dMMR mCRC that has progressed following treatment with CT. The dual regimen receives PMDA approval in Sept’2020 for MSI-H unresectable, advanced or recurrent colorectal cancer progressing after CT

Click here to­ read full press release/ article | Ref: BMS | Image: TAPinto

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post